Molecular Imaging and Biology

, Volume 8, Issue 5, pp 309–314 | Cite as

2-Deoxy-2-[18F]fluoro-d-glucose-Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Diagnosis of Patients with Recurrent Papillary Thyroid Cancer

  • Andrei Iagaru
  • Rinat Masamed
  • Peter A. Singer
  • Peter S. Conti
Research Article
First Online:

Abstract

Objective

2-Deoxy-2-[F-18]fluoro-d-glucose positron emission tomography (FDG-PET) has an established role in restaging of various cancers, including papillary and undifferentiated thyroid carcinoma, but detection rates are variable in the published literature. We were therefore prompted to review our experience with FDG-PET in detection of recurrent papillary thyroid cancer (PTC).

Methods

This is a retrospective study (April 1, 1995–March 31, 2005) of 21 patients with histologic diagnosis of PTC who had PET examinations. The group included seven men and 14 women, with age range of 26–75 years (average 50 ± 16). The PET scan request was triggered by rising levels of thyroglobulin (Tg) in the presence of a negative iodine-131 scan.

Results

Recurrent/metastatic disease was identified by PET in 16 (76%) of the 21 patients with PTC. The sensitivity and specificity of FDG-PET for disease detection in this cohort were 88.2% [95% confidence interval (CI), 65.7–96.7] and 75% (95% CI, 30.1–95.4), respectively. The Tg levels were 1.0–10.4 ng/ml (average, 4.52 ng/ml) in the patients with negative PET scans and 1.0–38 ng/ml (average, 16.8 ng/ml) in patients with positive scans. The lesions were located in the cervical lymph nodes (8), thyroid bed (4), lungs (4), and mediastinal lymph nodes (2).

Conclusion

Our study confirms the feasibility of PET in detection of residual/recurrence of PTC, with sensitivity of 88.2% (95% CI, 65.7–96.7) and specificity of 75% (95% CI, 30.1–95.4). Detectable levels of Tg, even in the presence of negative I-131 scan or anatomic imaging, should prompt restaging with FDG-PET.

Key words

Thyroid cancer FDG PET/CT 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Jemal A, Murray T, Ward E, et al. (Jan‐Feb 2005) Cancer statistics, 2005. CA Cancer J Clin 55(1):10–30PubMedCrossRefGoogle Scholar
  2. 2.
    Polednak AP (15 Nov 1994) Trends in cancer incidence in Connecticut, 1935–1991. Cancer 74(10):2863–2872PubMedCrossRefGoogle Scholar
  3. 3.
    Mack WJ, Preston-Martin S (1998) Epidemiology of thyroid cancer. In: Fagin JA (ed) Thyroid Cancer. Boston: Kluwer Academic Publishers, p 1Google Scholar
  4. 4.
    Pal T, Vogl FD, Chappuis PO, et al. (Nov 2001) Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 86(11):5307–5312PubMedCrossRefGoogle Scholar
  5. 5.
    Mazzaferri EL, Jhiang SM (Nov 1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97(5):418–428PubMedCrossRefGoogle Scholar
  6. 6.
    Siironen P, Louhimo J, Nordling S, et al. (3 May 2005) Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol 26(2):57–64PubMedCrossRefGoogle Scholar
  7. 7.
    Navarro Silvera SA, Miller AB, Rohan TE (1 Sep 2005) Risk factors for thyroid cancer: a prospective cohort study. Int J Cancer 116(3):433–438PubMedCrossRefGoogle Scholar
  8. 8.
    Wang W, Macapinlac H, Larson SM, et al. (Jul 1999) [18F]-2-Fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84(7):2291–2302PubMedCrossRefGoogle Scholar
  9. 9.
    Yeo JS, Chung JK, So Y, et al. (Feb 2001) F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 23(2):94–103PubMedCrossRefGoogle Scholar
  10. 10.
    McDougall IR, Davidson J, Segall GM (May 2001) Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun 22(5):485–492PubMedCrossRefGoogle Scholar
  11. 11.
    Jadvar H, McDougall IR, Segall GM (Jun 1998) Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography. Nucl Med Commun 19(6):547–554PubMedCrossRefGoogle Scholar
  12. 12.
    Cohen JB, Kalinyak JE, McDougall IR (Oct 2003) Modern management of differentiated thyroid cancer. Cancer Biother Radiopharm 18(5):689–705PubMedCrossRefGoogle Scholar
  13. 13.
    Clark JR, Lai P, Hall F, Borglund A, Eski S, Freeman JL (Apr 2005) Variables predicting distant metastases in thyroid cancer. Laryngoscope 115(4):661–667PubMedGoogle Scholar
  14. 14.
    Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA (Aug 1999) Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9(8):797–804PubMedCrossRefGoogle Scholar
  15. 15.
    Iwata M, Kasagi K, Misaki T, et al. (Apr 2004) Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 31(4):491–498PubMedCrossRefGoogle Scholar
  16. 16.
    Cohen EG, Tuttle RM, Kraus DH (Feb 2003) Postoperative management of differentiated thyroid cancer. Otolaryngol Clin North Am 36(1):129–157PubMedCrossRefGoogle Scholar
  17. 17.
    Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ (Jun 2000) FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 41(6):1010–1015PubMedGoogle Scholar
  18. 18.
    Shiga T, Tsukamoto E, Nakada K, et al. (Mar 2001) Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 42(3):414–419PubMedGoogle Scholar
  19. 19.
    Chung JK, So Y, Lee JS, et al. (Jun 1999) Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 40(6):986–992PubMedGoogle Scholar
  20. 20.
    Grunwald F, Kalicke T, Feine U, et al. (Dec 1999) Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26(12):1547–1552PubMedCrossRefGoogle Scholar
  21. 21.
    Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, et al. (Jun 2000) Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg 179(6):457–461PubMedCrossRefGoogle Scholar
  22. 22.
    Nahas Z, Goldenberg D, Fakhry C, et al. (Feb 2005) The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 115(2):237–243PubMedCrossRefGoogle Scholar

Copyright information

© Academy of Molecular Imaging 2006

Authors and Affiliations

  • Andrei Iagaru
    • 1
    • 4
  • Rinat Masamed
    • 2
  • Peter A. Singer
    • 3
  • Peter S. Conti
    • 1
  1. 1.PET Imaging Science CenterKeck School of Medicine of USCLos AngelesUSA
  2. 2.Keck School of Medicine of USCLos AngelesUSA
  3. 3.Division of EndocrinologyKeck School of Medicine of USCLos AngelesUSA
  4. 4.Division of Nuclear MedicineStanford University Medical CenterStanfordUSA

Personalised recommendations